ErVimmune | $19,917,795 | (Jan 21, 2026)
Statusphere | $18,000,000 | (Jan 21, 2026)
Think Bioscience | $55,000,000 | (Jan 21, 2026)
Certified by Founder
Lodge
Infinitopes
start up
United Kingdom
- Oxford, Oxfordshire
- 21/01/2026
- Seed
- $15,400,000
Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.
- Industry Biotechnology Research
- Website https://www.infinitopes.com/
- LinkedIn https://www.linkedin.com/company/infinitopes/
Related People
Senthil ChinnakannanCo Founder
United Kingdom -
Oxford, England
Molecular virologist/vaccinologist with expertise in multiple antigen/epitope vaccine design for Adeno/MVA viral vectors, passionate about translational research. Interests: Adeno/MVA viral vectors, therapeutic hepatitis B vaccine, prophylactic hepatitis C vaccine, therapeutic cancer vaccine
POINT.LAZ | $3,000,000 | (Jan 21, 2026)
Jetson | $50,000,000 | (Jan 21, 2026)
BrightInsight | $13,000,000 | (Jan 21, 2026)
Formulary Financial | $4,600,000 | (Jan 21, 2026)
Ultra Pouches | $11,000,000 | (Jan 21, 2026)
XBuild | $19,000,000 | (Jan 21, 2026)
Dam Secure | $4,000,000 | (Jan 21, 2026)
Cosmos | $15,000,000 | (Jan 21, 2026)